The complete nucleotide sequence and functional organization of Bacillus subtilis bacteriophage SPP1.

J. Alonso,G. Lüder,A. Stiege,S. Chai,F. Weise,T. Trautner

DOI: https://doi.org/10.1016/S0378-1119(97)00547-7

IF: 3.913

1997-12-19

Gene

Abstract:

What problem does this paper attempt to address?

Polymorphisms Involving the Pneumocystis Jirovecii-Related Genes in AIDS Patients in Eastern China.

Mengyan Wang,Xiaoke Xu,Yongzheng Guo,Ran Tao,Caiqin Hu,Xiaotian Dong,Ying Huang,Biao Zhu

DOI: https://doi.org/10.1016/j.meegid.2019.103955

IF: 4.393

2019-01-01

Infection Genetics and Evolution

Abstract:Objective: To investigate the genetic polymorphisms of mitochondrial large ribosomal subunit (mtLSU)-rRNA, dihydrofolate reductase (DHFR), dihydropteroate synthase (DHPS), cytochrome b (CYB), and superoxide dismutase (SOD) genes and its correlation with clinical outcomes of Pneumocystis jirovecii pneumonia in acquired immune deficiency(AIDS) patients. Methods: Eighty AIDS patients with P. jirovecii pneumonia that were admitted to our hospital from 2016 to 2018 were included in this study. Their demographic information and clinical data were collected, as well as corresponding saliva specimens for PCR and sequencing of mtLSU-rRNA, DHFR, DHPS, CYB, and SOD genes to analyze genetic polymorphisms, different polymorphic combinations, and clinical outcomes. Results: Of the 80 saliva specimens, mtLSU-rRNA was successfully amplified and sequenced in 30 cases; CYB was successfully amplified and sequenced in 26 cases; and SOD, DHFR, and DHPS were successfully amplified and sequenced in 18 cases. These results indicate that The mtLSU-rRNA, CYB, and SOD genes were highly polymorphic. mt85T and CYB1 were the variants dominantly detected at the mtLSU-rRNA and CYB loci, respectively. The SOD1 and SOD2 variants (each in 50% of the cases) were detected at the SOD locus. Among the 18 cases that were successfully amplified and sequenced for DHFR and DHPS, three DHFR nonsense mutations and no DHPS mutation were observed. The mt85C, CYB1, SOD1, and DHFR312T genes harbored common polymorphisms (n = 4; 22.22%) and the mt85T, CYB1, SOD1, DHFR312T genes were associated with poor clinical outcomes. Conclusion: The types of genetic polymorphisms and polymorphic combinations of mtLSU-rRNA, DHFR, DHPS, CYB, and SOD in P. jirovecii were related to the clinical outcomes of patients with P. jirovecii pneumonia in Zhejiang Province, China.
Diagnostic Value of Fluorescence Real-Time PCR for Pneumocystis Pneumonia in AIDS Patients

Zhu Mingli,Ye Ning,Li Xixi,Shi Jinchuan,Zhang Zhongdong,Ye Rongxia,Yu Jianhua,Liu Shourong

DOI: https://doi.org/10.3760/cma.j.issn.1673-4149.2019.02.003

2019-01-01

Abstract:Objective To investigate the value of fluorescence real-time PCR (RT-PCR) in diagnosing pneumocystis pneumonia (PCP) in AIDS patients.Methods One hundred and nine AIDS patients with a clinical suspicion of PCP in Xixi Hospital from 2013 to 2016 were enrolled.Detection results of sputum and Bronchoalveolar lavage fluid(BALF) samples were compared by RT-PCR and PCR-sequence analysis.Results The total positive rates of RT-PCR and PCR-sequence analysis were 57.8％ and 60.6％,respectively in 93 sputum samples and 16 BALF samples.The result of RT-PCR was in good correlation with PCR-sequence analysis with the sensitivity of 87.9％ (58/66),the specificity of 88.4％ (38/43),the positive predictive value of 92.1％ and the negative predictive value of 82.6％.Sensitivity and specificity of RT-PCR in BALF specimens were both 100.0％,which were better than those in sputum samples.Conclusions RT-PCR has good sensitivity and specificity for the diagnosis of AIDS patients with PCP,and the detection effect in BALF is better than in sputum specimens.This method is helpful for rapid,sensitive and specific detection of PCP.
Diagnosing Pneumocystis jirovecii pneumonia: A review of current methods and novel approaches

Marjorie Bateman,Rita Oladele,Jay K Kolls

DOI: https://doi.org/10.1093/mmy/myaa024

2020-11-10

Abstract:Pneumocystis jirovecii can cause life-threatening pneumonia in immunocompromised patients. Traditional diagnostic testing has relied on staining and direct visualization of the life-forms in bronchoalveolar lavage fluid. This method has proven insensitive, and invasive procedures may be needed to obtain adequate samples. Molecular methods of detection such as polymerase chain reaction (PCR), loop-mediated isothermal amplification (LAMP), and antibody-antigen assays have been developed in an effort to solve these problems. These techniques are very sensitive and have the potential to detect Pneumocystis life-forms in noninvasive samples such as sputum, oral washes, nasopharyngeal aspirates, and serum. This review evaluates 100 studies that compare use of various diagnostic tests for Pneumocystis jirovecii pneumonia (PCP) in patient samples. Novel diagnostic methods have been widely used in the research setting but have faced barriers to clinical implementation including: interpretation of low fungal burdens, standardization of techniques, integration into resource-poor settings, poor understanding of the impact of host factors, geographic variations in the organism, heterogeneity of studies, and limited clinician recognition of PCP. Addressing these barriers will require identification of phenotypes that progress to PCP and diagnostic cut-offs for colonization, generation of life-form specific markers, comparison of commercial PCR assays, investigation of cost-effective point of care options, evaluation of host factors such as HIV status that may impact diagnosis, and identification of markers of genetic diversity that may be useful in diagnostic panels. Performing high-quality studies and educating physicians will be crucial to improve the rates of diagnosis of PCP and ultimately to improve patient outcomes.
Preventive Treatment of Migraine with Mini‐Doses of Danitracene

F. Sulman,Y. Pfeifer,E. Superstine

DOI: https://doi.org/10.1111/j.1526-4610.1977.hed1705203.x

1977-11-01

Abstract:SYNOPSIS
Recent Advances in the Diagnosis of Pneumocystis Pneumonia.

Yinggai Song,Yi Ren,Xiaowen Wang,Ruoyu Li

DOI: https://doi.org/10.3314/mmj.16-00019

2016-01-01

Medical Mycology Journal

Abstract:Pneumocystis jirovecii is a prototypical opportunistic pathogen, causing an asymptomatic or mild infection in normal hosts and fulminating pneumonia (Pneumocystis pneumonia, PCP) in immunocompromised hosts. PCP is a leading cause of morbidity and mortality in immunocompromised patients such as AIDS patients. Microscopic detection of cysts and trophic forms of P. jirovecii in respiratory secretions is simple and useful but may underestimate the P. jirovecii infection. Conventional polymerase chain reaction (PCR) and nested PCR increase the sensitivity and specificity to identify PCP and provide an approach to discriminate PCP from pulmonary P. jirovecii colonization, but the targeted genes and cut-off value from quantitative real-time PCR remain to be determined. Serum (1-3)-β-D-glucan level and the specific serum antibody titer are ancillary indicators for PCP diagnosis. The successful cultivation of P. jirovecii in vitro is an important progress for PCP research. The diagnosis of PCP relies on the combination of these laboratory examinations as well as the clinical presentations.
B-204 A Real-time Probe-based PCR Assay for Detection of Pneumocystis Pneumonia

Z Zhou,S Li,D Jiang,Z Wang,Y Wang,Y Zhang,H Wang,Y Su

DOI: https://doi.org/10.1093/clinchem/hvae106.564

IF: 12.114

2024-10-01

Clinical Chemistry

Abstract:Abstract Background Pneumocystis jirovecii is an atypical opportunistic fungus with lung tropism and worldwide distribution that continues to be one of the major opportunistic pathogens causing severe Pneumocystis pneumonia (PcP) in individuals with acquired immune deficiency syndrome (AIDS) and patients with immunosuppression due to other causes. Widespread prophylaxis and treatment for P. jirovecii with sulfa drugs have decreased the incidence of PcP, but concerns have been raised about the possible emergence of P. jirovecii isolates resistant to these drugs. Point mutations in this gene have been associated with prior exposure to sulfa drugs in other microorganisms, the polymorphic positions 165 and 171, which lead to an amino acid change at positions 55 (Thr55Ala) and 57 (Pro57Ser) of the polypeptide chain, respectively. Fluorescent PCR technology can detect the nucleic acid fragments of P. jirovecii in patients' serum, alveolar perfusion fluid (BALF) and tissue samples, and further identify drug-resistant mutations, which is of great significance for early clinical and accurate initiation of antifungal therapy. MycoMDx Pneumocystis Jirovecii PCR Assay is the use of PCR-fluorescence probe method, combined with other methods to achieve the auxiliary diagnosis of P. jirovecii infection and resistance to sulfonamides (Fig. 1). Methods In this study, we did a performance evaluation of the MycoMDx Pneumocystis Jirovecii PCR Assay (CE-approved), including diagnostic sensitivity and specificity, the limit of detection (LoD), precision and stability. The above PCR assay reagents were developed and produced by Dynamiker Biotechnology (Tianjin) Co., Ltd. Results The sensitivity and specificity of the PCR assay reagents were above 90%, the LoD was 1000 copies/mL, and the precision and stability were in accordance with the requirements (CV≤5%). Conclusions The MycoMDx Pneumocystis Jirovecii PCR Assay has great clinical value by providing a rapid and reliable test to aid in early diagnosis.

medical laboratory technology
[Evaluation of Real-Time Polymerase Chain Reaction in Pneumocystis jirovecii Laboratory Diagnosis]

Soykan Özkoç,Ceren Ergüden Gürbüz,Ayça Arzu Sayıner,Songül Bayram Delibaş

DOI: https://doi.org/10.5578/mb.69711

Abstract:Pneumocystis jirovecii is a human-specific species and causes fatal infections like P.jirovecii pneumonia (PCP) in immunocompromised persons. Although direct microscopy is the gold standard in the diagnosis of the microorganism, molecular methods such as polymerase chain reaction (PCR) are needed in non-human immune deficiency virus (HIV) immunosuppresive patients with low P.jirovecii burden. In this study, we aimed to evaluate the value of real-time PCR (Rt-PCR) in the laboratory diagnosis of P.jirovecii. Bronchoalveolar lavage (BAL) specimens of 658 patients sent to Dokuz Eylul University Hospital Central Medical Parasitology Laboratory on suspicion of PCP were included in the study. BAL fluids were evaluated for identification of P.jirovecii mitochondrial gene coding ribosomal large subunit (mtLSUrRNA) using Rt-PCR. In addition, Giemsa and Gomori's methenamine silver (GMG) staining assays were applied to all samples and nested PCR (n-PCR) assay was applied to positive samples detected by real time PCR. Ninety-two (14.3%) of these samples were positive by Rt-PCR. Of these 92 patients, 85 (92.4%) were positive with n-PCR. Only seven of the specimens had P.jirovecii cysts and trophozoites with microscopic examination. The mean cycle threshold (CT ) value of Rt-PCR positive patients was 29.7 (18.17 ≤ CT ≤ 37.96). P.jirovecii load in these patients was calculated as 2.6 x 101-6.15 x 107 copies/ml. The difference between the mean CT values of n-PCR positive and negative results was statistically significant (p< 0.01). The CT values of Rt-PCR of the samples with positive microscopy were; 18.2, 20.9, 22.2, 24.3, 24.7, 26.5, 29.7. The difference between the CT means of the samples with positive and negative microscopy was statistically significant (p< 0.05). When positive patients were grouped according to their diagnosis; the lowest mean CT value (CTmean= 24.8) was found in HIV-positive patients. On the other hand, CT values were found to be significantly lower in the organ transplantation patients (CTmean= 26.15) and in the collagen-vascular-inflammatory patient group (CTmean= 27.8). This study demonstrated that Rt-PCR was the effective method in the diagnosis of P.jirovecii in the laboratory. Conventional n-PCR method was found to be more unsuccessful than Rt-PCR in the presence of very low density organism; direct microscopy is generally found to be positive in samples with a higher burden of P.jirovecii.
Determining Pneumocystis jirovecii Colonisation from Infection Using PCR-Based Diagnostics in HIV-Negative Individuals

Anna Louise Watson,John Woodford,Sumudu Britton,Rita Gupta,David Whiley,Kate McCarthy

DOI: https://doi.org/10.3390/diagnostics14010114

IF: 3.6

2024-01-04

Diagnostics

Abstract:Background: Pneumocystis jirovecii pneumonia is increasingly diagnosed with highly sensitive PCR diagnostics in immunocompromised, HIV-negative individuals. We assessed the performance of our in-house quantitative PCR with the aim to optimise interpretation. Methods: Retrospective audit of all positive P. jirovecii qPCRs on induced sputum or BAL fluid at a single centre from 2012 to 2023. Medical and laboratory records were analysed and people with HIV were excluded. Cases were categorised as colonisation, high-probability PCP or uncertain PCP infection against a clinical gold standard incorporating clinico-radiological data. Quantitative PCR assay targeting the 5s gene was utilised throughout the time period. Results: Of the 82 positive qPCRs, 28 were categorised as high-probability PCP infection, 30 as uncertain PCP and 24 as colonisation. There was a significant difference in qPCR values stratified by clinical category but not respiratory sample type. Current assay performance with a cutoff of 2.5 × 105 copies/mL had a sensitivity of 50% (95% CI, 30.65–69.35%) and specificity of 83.33% (95% CI, 62.62–95.26%). Youden Index calculated at 6.5 × 104 copies/mL had a sensitivity of 75% (56.64–87.32%, 95% CI) and specificity of 66.67% (46.71–82.03%, 95% CI). High and low cutoffs were explored. Significant variables associated with infection were age > 70 years old, the presence of fever, hypoxia or ground glass changes. Conclusions: A single qPCR cutoff cannot reliably determine P. jirovecii infection from colonisation. Low and high cutoffs are useful, however, a large “possible infection” cohort will remain where interpretation of clinic-radiological factors remains essential. Standardisation of assays with prospective validation in specific immunocompromised groups will allow greater generalisability and allow large-scale prospective assay validation to be performed.

medicine, general & internal
Use of Real-Time Polymerase Chain Reaction for the Diagnosis of Pneumocystis Pneumonia in Immunocompromised Patients: a Meta-Analysis.

Hanssa Summah,Zhu Ying-gang,Matthew E. Falagas,Evridiki K. Vouloumanou,Qu Jie-ming

DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20122506

IF: 6.133

2013-01-01

Chinese Medical Journal

Abstract:BACKGROUND:The diagnosis of Pneumocystis pneumonia (PCP) in immunocompromised patients is still challenging today due to the absence of an in vitro culture system and the low diagnostic accuracy of microscopic examinations. Herein, we performed a meta-analysis to evaluate the accuracy of real-time polymerase chain reaction (PCR) in the diagnosis of PCP.METHODS:We searched Web of Knowledge and Medline from 1990 to May 2010 for studies reporting diagnostic accuracy data regarding the use of real-time PCR in the diagnosis of PCP in immunocompromised patients.RESULTS:Ten individual studies were included. Overall, the sensitivity of real-time PCR was 97% (95%CI: 93% - 99%); the specificity was 94% (95%CI: 90% - 96%). The area under the HSROC curve (95%CI) for real-time PCR was 0.99 (0.97 - 0.99). In a subgroup analysis regarding studies involving HIV patients among the study population, the sensitivity and specificity were 97% (95%CI: 93% - 99%) and 93% (95%CI: 89% - 96%), respectively. Regarding studies using Bronchoalveolar lavage (BAL) samples only: sensitivity = 98% (95%CI: 94% - 99%); specificity = 93% (95%CI: 89% - 96%), respectively. Regarding studies using microscopy as a reference standard: sensitivity = 97% (95%CI: 92% - 99%); specificity = 93% (95%CI: 88% - 96%). However, high between-study statistical heterogeneity was observed in all analyses.CONCLUSIONS:Real-time PCR has a good diagnostic accuracy and may provide a useful adjunctive tool for the diagnosis of PCP in immunocompromised patients. Further studies are needed in order to identify any differences in the diagnostic performance of real-time PCR in HIV and non-HIV immunocompromised patients.
Strengths and limitations of molecular diagnostics for Pneumocystis jirovecii pneumonia

Lottie Brown,Alexandre Alanio,Mario Cruciani,Rosemary Barnes,J. Peter Donnelly,Juergen Loeffler,Riina Rautemaa-Richardson,P. Lewis White

DOI: https://doi.org/10.1080/14737159.2024.2405920

2024-11-27

Expert Review of Molecular Diagnostics

Abstract:Introduction While Pneumocystis pneumonia (PcP) remains a major AIDS-defining disease, the majority of cases of PcP now present in the HIV-negative cohort, causing significant mortality. PcP PCR diagnosis is not novel, and the optimal route of diagnosis remains unclear, with an imperfect reference method and complexity in result interpretation for alternative tests.

pathology
Polymerase Chain Reaction on Respiratory Tract Specimens of Immunocompromised Patients to Diagnose Pneumocystis Pneumonia: A Systematic Review and Meta-analysis

Lottie Brown,Riina Rautemaa-Richardson,Carlo Mengoli,Alexandre Alanio,Rosemary A Barnes,Stéphane Bretagne,Sharon C A Chen,Catherine Cordonnier,J Peter Donnelly,Werner J Heinz,Brian Jones,Lena Klingspor,Juergen Loeffler,Thomas R Rogers,Eleanor Rowbotham,P Lewis White,Mario Cruciani

DOI: https://doi.org/10.1093/cid/ciae239

IF: 20.999

2024-06-13

Clinical Infectious Diseases

Abstract:Background This meta-analysis examines the comparative diagnostic performance of polymerase chain reaction (PCR) for the diagnosis of Pneumocystis pneumonia (PCP) on different respiratory tract samples, in both human immunodeficiency virus (HIV) and non-HIV populations. Methods A total of 55 articles met inclusion criteria, including 11 434 PCR assays on respiratory specimens from 7835 patients at risk of PCP. QUADAS-2 tool indicated low risk of bias across all studies. Using a bivariate and random-effects meta-regression analysis, the diagnostic performance of PCR against the European Organisation for Research and Treatment of Cancer–Mycoses Study Group definition of proven PCP was examined. Results Quantitative PCR (qPCR) on bronchoalveolar lavage fluid provided the highest pooled sensitivity of 98.7% (95% confidence interval [CI], 96.8%–99.5%), adequate specificity of 89.3% (95% CI, 84.4%–92.7%), negative likelihood ratio (LR−) of 0.014, and positive likelihood ratio (LR+) of 9.19. qPCR on induced sputum provided similarly high sensitivity of 99.0% (95% CI, 94.4%–99.3%) but a reduced specificity of 81.5% (95% CI, 72.1%–88.3%), LR− of 0.024, and LR+ of 5.30. qPCR on upper respiratory tract samples provided lower sensitivity of 89.2% (95% CI, 71.0%–96.5%), high specificity of 90.5% (95% CI, 80.9%–95.5%), LR− of 0.120, and LR+ of 9.34. There was no significant difference in sensitivity and specificity of PCR according to HIV status of patients. Conclusions On deeper respiratory tract specimens, PCR negativity can be used to confidently exclude PCP, but PCR positivity will likely require clinical interpretation to distinguish between colonization and active infection, partially dependent on the strength of the PCR signal (indicative of fungal burden), the specimen type, and patient population tested.

immunology,infectious diseases,microbiology
Development and evaluation of a real-time PCR assay for detection of Pneumocystis jiroveci

D Bandt,S Monecke

DOI: https://doi.org/10.1111/j.1399-3062.2007.00246.x

Abstract:Pneumocystis jiroveci is an important agent of pneumonia in immunocompromised hosts. Usually, this pathogen is detected by Giemsa or direct fluorescence stains of bronchoalveolar lavage (BAL) fluids. Microscopic methods, however, have 2 disadvantages. P. jiroveci is not stable outside the human body, which means that slow sample transport might result in false-negative results. Additionally, exact quantification, which is needed for therapy monitoring, is not possible. In this study, we developed a real-time polymerase chain reaction assay for the LightCycler. Two Pneumocystis-specific TaqMan systems, one based on the sequence of the 5.8S ribosomal gene and another one targeting the dihydrofolate reductase gene were evaluated. Additionally, the amount of human DNA in the sample was measured by a TaqMan assay based on the human albumin gene, allowing assessment of sample quality and quantification normalized on sample concentration. For clinical evaluation, 69 BAL specimens from 26 positive patients as well as 60 negative controls were tested. Both systems were able to detect all proven cases of Pneumocystis pneumonia. Differentiation of carriage, asymptomatic reactivation, and clinical infection as well as normalized quantification by calculating the ratio of Pneumocystis DNA to human DNA are discussed.
Quantitative real time PCR for distinction between Pneumocystis jirovecii infection/colonization in hospitalized patients

Faezeh Rouhi,Mahzad Erami,Sepide Rastgufar,Maryam Jahani,Shima Aboutalebian,Sajedeh Soltani,Hamed Fakhim,Hossein Mirhendi

DOI: https://doi.org/10.3389/fcimb.2024.1426200

IF: 6.073

2024-09-25

Frontiers in Cellular and Infection Microbiology

Abstract:Background: Identification of the opportunistic fungus Pneumocystis jirovecii in respiratory specimens presents challenges, particularly in differentiating between colonization and active infection. The present study assessed a probe-based real time PCR (qPCR) diagnostic effectiveness in patients with diverse underlying conditions, particularly those with COVID-19 and pulmonary insufficiency. Methods: To set up the qPCR, clinical samples from 281 patients with respiratory ailments were tested. Subsequently, a descriptive study was conducted on 112 patients with pulmonary insufficiency with and without COVID-19 suspected of P. jirovecii infection. All specimens were subjected to DNA extraction followed by nested PCR and qPCR targeting the mitochondrial large subunit (mtLSU)-rRNA gene. Results: Based on nested PCR and qPCR, P. jirovecii was identified in 40 out of 281 patients, with slight variations in positive samples observed across dilutions. Three patients who tested positive in nested PCR yielded negative results in probe-based qPCR. Conversely, three patients who tested positive in probe-based qPCR yielded negative results in nested PCR. Considering nested PCR as the golden standard, probe-based qPCR demonstrated good diagnostic performance, with 92.5% sensitivity and 98.7% specificity. Based on cycle threshold (Ct) values, the positive cases were categorized: ≤32 as infection, >35 as colonization, and a grey zone between these values (32 < X ≤ 35). The analysis of 112 PCP-suspected patients revealed a prevalence ranging from 6.25% (nested PCR) to 7% (probe-based qPCR). Conclusions: This study suggested Ct values to differentiate Pneumocystis pneumonia/colonization in immunocompromised patients. To further augment the diagnostic sensitivity, it is recommended to integrate qPCR results with clinical parameters and biomarkers to offer a more precise understanding of Pneumocystis -related conditions.

immunology,microbiology
Molecular Study of Pneumocystis jirovecii in Respiratory Samples of HIV Patients in Chile

Isabel Iturrieta-González,Carolina Chahin,Johanna Cabrera,Carla Concha,Pamela Olivares-Ferretti,Javier Briones,Fernando Vega,Luis Bustos-Medina,Flery Fonseca-Salamanca

DOI: https://doi.org/10.3390/jof10020117

2024-01-31

Journal of Fungi

Abstract:Pneumocystis is an opportunistic fungus that causes potentially fatal pneumonia (PCP) in immunocompromised patients. The objective of this study was to determine the prevalence of P. jirovecii in HIV patients through phenotypic and molecular study, to investigate the genetic polymorphisms of P. jirovecii at the mitochondrial gene mtLSU and at the nuclear dihydropteroate synthase gene (DHPS), and by analysis of molecular docking to study the effect of DHPS mutations on the enzymatic affinity for sulfamethoxazole. A PCP prevalence of 28.3% was detected, with mtLSU rRNA genotypes 3 (33.3%) and 2 (26.6%) being the most common. A prevalence of 6.7% (1/15) mutations in the DHPS gene was detected, specifically at codon 55 of the amino acid sequence of dihydropteroate synthase. Molecular docking analysis showed that the combination of mutations at 55 and 98 codons is required to significantly reduce the affinity of the enzyme for sulfamethoxazole. We observed a low rate of mutations in the DHPS gene, and molecular docking analysis showed that at least two mutations in the DHPS gene are required to significantly reduce the affinity of dihydropteroate synthase for sulfamethoxazole.

microbiology,mycology
Serum-based diagnosis of Pneumocystis pneumonia by detection of Pneumocystis jirovecii DNA and 1,3-β-D-glucan in HIV-infected patients: a retrospective case control study

Helena Hammarström,Anna Grankvist,Isabell Broman,Nahid Kondori,Christine Wennerås,Magnus Gisslen,Vanda Friman

DOI: https://doi.org/10.1186/s12879-019-4289-4

IF: 3.7

2019-07-23

BMC Infectious Diseases

Abstract:<h3 class="Heading">Background</h3><p class="Para"><em class="EmphasisTypeItalic">Pneumocystis jirovecii</em> pneumonia (PCP) is one of the most common HIV-related opportunistic infections. The diagnosis of PCP is based on analyses from respiratory tract specimens which may require the invasive procedure of a diagnostic bronchoscopy. The objective of this study was to evaluate the diagnostic potential of <em class="EmphasisTypeItalic">Pneumocystis jirovecii</em> PCR in serum combined with the 1,3-β-D-glucan (betaglucan) test for the diagnosis of PCP in HIV-infected patients.</p><h3 class="Heading">Methods</h3><p class="Para">This was a retrospective case-control study including serum samples from 26 HIV-infected patients with PCP collected within 5 days prior to the start of PCP treatment, 21 HIV-infected control subjects matched by blood CD4<sup>+</sup> cell counts, and 18 blood donors. The serum samples were analyzed for <em class="EmphasisTypeItalic">Pneumocystis jirovecii</em> PCR and betaglucan. The reference standard for PCP was based on previously described microbiological and clinical criteria.</p><h3 class="Heading">Results</h3><p class="Para">All patients with PCP had detectabe <em class="EmphasisTypeItalic">Pneumocystis jirovecii</em> DNA in serum yielding a sensitivity for the <em class="EmphasisTypeItalic">Pneumocystis jirovecii</em> PCR assay in serum of 100%. All blood donors had negative <em class="EmphasisTypeItalic">Pneumocystis</em> PCR in serum. The specificity when testing HIV-infected patients was 71%, but with a PCR Cycle threshold (Ct) value of 34 as cut-off the specificity was 90%. At a putative pretest probaility of 20%, the negative and positive predictive value for the <em class="EmphasisTypeItalic">Pneumocystis</em> PCR assay in serum was 0.99 and 0.71, respectively. Betaglucan with cut-off level 200 pg/ml combined with a positive <em class="EmphasisTypeItalic">Pneumocystis jirovecii</em> PCR result had sensitivity and specificity of 92 and 90%, respectively. The concentration of <em class="EmphasisTypeItalic">Pneumocystis jirovecii</em> DNA in serum samples, expressed by the PCR Ct values, correlated inversely to the betaglucan levels in serum.</p><h3 class="Heading">Conclusion</h3><p class="Para">In this case-control study including 70% of all HIV-infected patients with PCP treated at Sahlgrenska University Hospital during a time period of 13 years, <em class="EmphasisTypeItalic">Pneumocystis</em> PCR analysis on serum samples had a very high sensitivity and negative predictive value for the diagnosis of PCP in HIV-infected patients. A serum-based diagnostic procedure either based on <em class="EmphasisTypeItalic">Pneumocystis jirovecii</em> PCR alone or in combination with betaglucan analysis may thus be feasible and would facilitate the care of HIV-infected patients with suspected PCP.</p>

infectious diseases
Development of a Droplet Digital Polymerase Chain Reaction for Sensitive Detection of <i>Pneumocystis jirovecii</i> in Respiratory Tract Specimens

Jie Yi,Nan Wang,Jie Wu,Yueming Tang,Jingjia Zhang,Lingxiang Zhu,Xiao Rui,Yong Guo,Yingchun Xu

DOI: https://doi.org/10.3389/fmed.2021.761788

IF: 3.9

2021-01-01

Frontiers in Medicine

Abstract:Background: Pneumocystis jirovecii is a human-specific opportunistic fungus that causes Pneumocystis pneumonia (PCP), a life-threatening opportunistic lung infection that affects immunocompromised patients. P. jirovecii colonization may be linked to the transmission of the infection. The detection of P. jirovecii in immunocompromised patients is thus especially important. The low fungal load and the presence of PCR inhibitors limit the usefulness of quantitative PCR (qPCR) for accurate absolute quantification of P. jirovecii in specimens. Droplet digital PCR (ddPCR), however, presents a methodology that allows higher sensitivity and accuracy. Here, we developed a ddPCR method for detecting P. jirovecii DNA in respiratory specimens, and evaluated its sensitivity against qPCR.Materials and Methods: One bronchoalveolar fluid (BALF) sample each was collected from 82 patients with potential PCP to test the presence of P. jirovecii DNA using both ddPCR and qPCR, and samples with inconsistent results between the two methods were further tested by metagenomic next generation sequencing (mNGS). In addition, 37 sputum samples from 16 patients diagnosed with PCP, as well as continuous respiratory tract specimens from nine patients with PCP and treated with sulfonamides, were also collected for P. jirovecii DNA testing using both ddPCR and qPCR.Results: ddPCR and qPCR gave the same results for 95.12% (78/82) of the BALF samples. The remaining four specimens tested positive using ddPCR but negative using qPCR, and they were found to be positive by mNGS. Detection results of 78.37% (29/37) sputum samples were consistent between ddPCR and qPCR, while the other eight samples tested positive using ddPCR but negative using qPCR. The P. jirovecii load of patients with PCP decreased to undetectable levels after treatment according to qPCR, but P. jirovecii was still detectable using ddPCR.Conclusions: ddPCR was more sensitive than qPCR, especially at detecting low-pathogen-load P. jirovecii. Thus, ddPCR represents a useful, viable, and reliable alternative to qPCR in P. jirovecii testing in patients with immunodeficiency.
Development of a clinical risk score for the prediction of Pneumocystis jirovecii pneumonia in hospitalised patients

Benjamin Mappin-Kasirer,Olivier Del Corpo,Marc-Alexandre Gingras,Aaron Hass,Jimmy M Hsu,Cecilia T Costiniuk,Nicole Ezer,Richard S Fraser,Todd C Lee,Emily G McDonald

DOI: https://doi.org/10.1186/s12879-024-09957-y

2024-09-27

Abstract:Background: The performance and availability of invasive and non-invasive investigations for the diagnosis of Pneumocystis jirovecii pneumonia (PCP) vary across clinical settings. Estimating the pre-test probability of PCP is essential to the optimal selection and interpretation of diagnostic tests, such as the 1,3-β-D-glucan assay (BDG), for the prioritization of bronchoscopy, and to guide empiric treatment decisions. We aimed to develop a multivariable risk score to estimate the pre-test probability of PCP. Methods: The score was developed from a cohort of 626 individuals who underwent bronchoscopy for the purposes of identifying PCP in a Canadian tertiary-care centre, between 2015 and 2018. We conducted a nested case-control study of 57 cases and 228 unmatched controls. Demographic, clinical, laboratory, and radiological data were included in a multivariable logistic regression model to estimate adjusted odds ratios for PCP diagnosis. A clinical risk score was derived from the multivariable model and discrimination was assessed by estimating the score's receiver operating characteristic curve. Results: Participants had a median age of 60 years (interquartile range [IQR] 49-68) and 115 (40%) were female; 40 (14%) had HIV and 49 (17%) had a solid organ transplant (SOT). The risk score included prior SOT or HIV with CD4 ≤ 200/µL (+ 2), serum lactate dehydrogenase ≥ 265.5 IU/mL (+ 2), radiological pattern typical of PCP on chest x-ray (+ 2) or CT scan (+ 2.5), and PCP prophylaxis with trimethoprim-sulfamethoxazole (-3) or other antimicrobials (-2). The median score was 4 points (IQR, 2-4.5) corresponding to a 28% probability of PCP. The risk prediction model had good discrimination with a c-statistic of 0.79 (0.71-0.84). Given the operating characteristics of the BDG assay, scores ≤ 3 in patients without HIV, and ≤ 5.5 in those with HIV, paired with a negative BDG, would be expected to rule out PCP with 95% certainty. Conclusion: We propose the PCP Score to estimate pre-test probability of PCP. Once validated, it should help clinicians determine which patients to refer for invasive investigations, when to rely on serological testing, and in whom to consider pre-emptive treatment.
Predictive models-assisted diagnosis of AIDS-associated Pneumocystis jirovecii pneumonia in the emergency room, based on clinical, laboratory, and radiological data

Oscar José Chagas,Fabio Augusto Rodrigues Gonçalves,Priscila Paiva Nagatomo,Renata Buccheri,Vera Lucia Pereira-Chioccola,Gilda Maria Barbaro Del Negro,Gil Benard

DOI: https://doi.org/10.1038/s41598-024-61174-4

IF: 4.6

2024-05-17

Scientific Reports

Abstract:We assessed predictive models (PMs) for diagnosing Pneumocystis jirovecii pneumonia (PCP) in AIDS patients seen in the emergency room (ER), aiming to guide empirical treatment decisions. Data from suspected PCP cases among AIDS patients were gathered prospectively at a reference hospital's ER, with diagnoses later confirmed through sputum PCR analysis. We compared clinical, laboratory, and radiological data between PCP and non-PCP groups, using the Boruta algorithm to confirm significant differences. We evaluated ten PMs tailored for various ERs resource levels to diagnose PCP. Four scenarios were created, two based on X-ray findings (diffuse interstitial infiltrate) and two on CT scans ("ground-glass"), incorporating mandatory variables: lactate dehydrogenase, O2 sat , C-reactive protein, respiratory rate (> 24 bpm), and dry cough. We also assessed HIV viral load and CD4 cell count. Among the 86 patients in the study, each model considered either 6 or 8 parameters, depending on the scenario. Many models performed well, with accuracy, precision, recall, and AUC scores > 0.8. Notably, nearest neighbor and naïve Bayes excelled (scores > 0.9) in specific scenarios. Surprisingly, HIV viral load and CD4 cell count did not improve model performance. In conclusion, ER-based PMs using readily available data can significantly aid PCP treatment decisions in AIDS patients.

multidisciplinary sciences
Use of Indirect Immunofluorescence Microscopy in the Diagnosis of AIDS Patients with Pneumocystis Pneumonia

Liu Yan,Zhang Songping,Shi Jinchuan,Yu Jianhua,Guo Jianchun

DOI: https://doi.org/10.3760/cma.j.issn.1003-9279.2014.02.021

2014-01-01

Abstract:Objective To detect Pneumocystis carinii in sputum in patients with AIDS complicated with Pneumocystis pneumoniae (PCP)by using indirect immunofluorescence microscopy.Methods Indirect immunofluorescence microscopy was used to detect Pneumocystis carinii in sputum samples of 53 patients with AIDS complicated with suspected PCP,observed the clinical effects and outcomes of the patients.Results Of the 53 cases,30 cases were positive.The positive rate was 56.6％.Patients with positive CD4+ T lymphocyte count was in average 33.33 ± 42.99/μl,23 patients who were negative for PCP had a CD4+ T lymphocyte count of 104.13 ± 77.87/μ1.Conclusions The indirect immunofluorescence microscopy was specific rapid and sensitive method in detection of pneumocystis infection in HIV infected patients.
Using Routine Laboratory Markers and Immunological Indicators for Predicting Pneumocystis jiroveci Pneumonia in Immunocompromised Patients

Guoxing Tang,Shutao Tong,Xu Yuan,Qun Lin,Ying Luo,Huijuan Song,Wei Liu,Shiji Wu,Liyan Mao,Weiyong Liu,Yaowu Zhu,Ziyong Sun,Feng Wang

DOI: https://doi.org/10.3389/fimmu.2021.652383

IF: 7.3

2021-04-12

Frontiers in Immunology

Abstract:Background Pneumocystis jiroveci pneumonia (PJP) is the most common opportunistic infection in immunocompromised patients. The accurate prediction of PJP development in patients undergoing immunosuppressive therapy remains challenge. Methods Patients undergoing immunosuppressive treatment and with confirmed pneumocystis jiroveci infection were enrolled. Another group of matched patients with immunosuppressant treatment but without signs of infectious diseases were enrolled to control group. Results A total of 80 (40 PJP, 40 non-PJP) participants were enrolled from Tongji Hospital. None of the patients were HIV positive. The routine laboratory indicators, such as LYM, MON, RBC, TP, and ALB, were significantly lower in PJP patients than in non-PJP patients. Conversely, LDH in PJP patients was significantly higher than in non-PJP controls. For immunological indicators, the numbers of T, B, and NK cells were all remarkably lower in PJP patients than in non-PJP controls, whereas the functional markers such as HLA-DR, CD45RO and CD28 expressed on CD4 + or CD8 + T cells had no statistical difference between these two groups. Cluster analysis showing that decrease of host immunity markers including CD3 + , CD4 + and CD8 + T cells, and increase of tissue damage marker LDH were the most typical characteristics of PJP patients. A further established model based on combination of CD8 + T cells and LDH showed prominent value in distinguishing PJP from non-PJP, with AUC of 0.941 (95% CI, 0.892-0.990). Conclusions A model based on combination of routine laboratory and immunological indicators shows prominent value for predicting the development of PJP in HIV-negative patients undergoing immunosuppressive therapy.

immunology

The complete nucleotide sequence and functional organization of Bacillus subtilis bacteriophage SPP1.

Polymorphisms Involving the Pneumocystis Jirovecii-Related Genes in AIDS Patients in Eastern China.

Diagnostic Value of Fluorescence Real-Time PCR for Pneumocystis Pneumonia in AIDS Patients

Diagnosing Pneumocystis jirovecii pneumonia: A review of current methods and novel approaches

Preventive Treatment of Migraine with Mini‐Doses of Danitracene

Recent Advances in the Diagnosis of Pneumocystis Pneumonia.

B-204 A Real-time Probe-based PCR Assay for Detection of Pneumocystis Pneumonia

[Evaluation of Real-Time Polymerase Chain Reaction in Pneumocystis jirovecii Laboratory Diagnosis]

Determining Pneumocystis jirovecii Colonisation from Infection Using PCR-Based Diagnostics in HIV-Negative Individuals

Use of Real-Time Polymerase Chain Reaction for the Diagnosis of Pneumocystis Pneumonia in Immunocompromised Patients: a Meta-Analysis.

Strengths and limitations of molecular diagnostics for Pneumocystis jirovecii pneumonia

Polymerase Chain Reaction on Respiratory Tract Specimens of Immunocompromised Patients to Diagnose Pneumocystis Pneumonia: A Systematic Review and Meta-analysis

Development and evaluation of a real-time PCR assay for detection of Pneumocystis jiroveci

Quantitative real time PCR for distinction between Pneumocystis jirovecii infection/colonization in hospitalized patients

Molecular Study of Pneumocystis jirovecii in Respiratory Samples of HIV Patients in Chile

Serum-based diagnosis of Pneumocystis pneumonia by detection of Pneumocystis jirovecii DNA and 1,3-β-D-glucan in HIV-infected patients: a retrospective case control study

Development of a Droplet Digital Polymerase Chain Reaction for Sensitive Detection of <i>Pneumocystis jirovecii</i> in Respiratory Tract Specimens

Development of a clinical risk score for the prediction of Pneumocystis jirovecii pneumonia in hospitalised patients

Predictive models-assisted diagnosis of AIDS-associated Pneumocystis jirovecii pneumonia in the emergency room, based on clinical, laboratory, and radiological data

Use of Indirect Immunofluorescence Microscopy in the Diagnosis of AIDS Patients with Pneumocystis Pneumonia

Using Routine Laboratory Markers and Immunological Indicators for Predicting Pneumocystis jiroveci Pneumonia in Immunocompromised Patients